Abstract

The current clinical study is aimed at evaluating the clinical relevance of an innovative device (called CyPaM2 device) that for the first time provides urologists with (i) a panoramic image of the bladder inner wall within the surgery time, and with (ii) a simultaneous (bimodal) display of fluorescence and white-light video streams during the fluorescence assisted–transurethral resection of bladder cancers procedure. The clinical relevance of this CyPaM2 device was evaluated on 10 patients according to three criteria (image quality, fluorescent lesions detection relevance, and ergonomics) compared with a reference medical device. Innovative features displayed by the CyPaM2 device were evaluated without any possible comparison: (i) simultaneous bimodal display of white-light and fluorescence video streams, (ii) remote light control, and (iii) time delay for the panoramic image building. The results highlight the progress to achieve in order to obtain a fully mature device ready for commercialization and the relevance of the innovative features proposed by the CyPaM2 device confirming their interest.

© 2019 Optical Society of America

Full Article  |  PDF Article
OSA Recommended Articles
3D reconstruction of cystoscopy videos for comprehensive bladder records

Kristen L. Lurie, Roland Angst, Dimitar V. Zlatev, Joseph C. Liao, and Audrey K. Ellerbee Bowden
Biomed. Opt. Express 8(4) 2106-2123 (2017)

Multimodal 3D cancer-mimicking optical phantom

Gennifer T. Smith, Kristen L. Lurie, Dimitar V. Zlatev, Joseph C. Liao, and Audrey K. Ellerbee Bowden
Biomed. Opt. Express 7(2) 648-662 (2016)

Registration of free-hand OCT daughter endoscopy to 3D organ reconstruction

Kristen L. Lurie, Roland Angst, Eric J. Seibel, Joseph C. Liao, and Audrey K. Ellerbee Bowden
Biomed. Opt. Express 7(12) 4995-5009 (2016)

References

  • View by:
  • |
  • |
  • |

  1. F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
    [Crossref]
  2. M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
    [Crossref]
  3. D. Trivedi and E. M. Messing, “Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria,” BMC Urol. 9, 13 (2009).
    [Crossref]
  4. A. Kumar, R. Kumar, and N. P. Gupta, “Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer,” Jpn. J. Clin. Oncol. 36, 172–175 (2006).
    [Crossref]
  5. S. Goodison, C. J. Rosser, and V. Urquidi, “Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests,” Mol. Diagn. Ther. 17, 71–84 (2013).
    [Crossref]
  6. W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
    [Crossref]
  7. G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Med. 11, 13 (2013).
    [Crossref]
  8. H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
    [Crossref]
  9. R. M. Valentine, S. H. Ibbotson, K. Wood, C. T. A. Brown, and H. Moseley, “Modelling fluorescence in clinical photodynamic therapy,” Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 12, 203–213 (2013).
    [Crossref]
  10. A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
    [Crossref]
  11. S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
    [Crossref]
  12. Great Britain, Parliament, House of Commons, Science and Technology Committee, Bridging the Valley of Death: Improving the Commercialisation of Research, Eighth Report of Session 2012-13, Report, Together with Formal Minutes, Oral and Written Evidence (The Stationery Office, 2013).
  13. S. Ali, C. Daul, E. Galbrun, F. Guillemin, and W. Blondel, “Anisotropic motion estimation on edge preserving Riesz wavelets for robust video mosaicing,” Pattern Recognit. 51, 425–442 (2016).
    [Crossref]
  14. K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
    [Crossref]
  15. S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
    [Crossref]
  16. S. Ali, C. Daul, E. Galbrun, and W. Blondel, “Illumination invariant optical flow using neighborhood descriptors,” Comput. Vis. Image Underst. 145, 95–110 (2016).
    [Crossref]

2018 (2)

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
[Crossref]

M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
[Crossref]

2016 (3)

W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
[Crossref]

S. Ali, C. Daul, E. Galbrun, F. Guillemin, and W. Blondel, “Anisotropic motion estimation on edge preserving Riesz wavelets for robust video mosaicing,” Pattern Recognit. 51, 425–442 (2016).
[Crossref]

S. Ali, C. Daul, E. Galbrun, and W. Blondel, “Illumination invariant optical flow using neighborhood descriptors,” Comput. Vis. Image Underst. 145, 95–110 (2016).
[Crossref]

2015 (2)

K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
[Crossref]

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

2013 (4)

S. Goodison, C. J. Rosser, and V. Urquidi, “Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests,” Mol. Diagn. Ther. 17, 71–84 (2013).
[Crossref]

G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Med. 11, 13 (2013).
[Crossref]

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

R. M. Valentine, S. H. Ibbotson, K. Wood, C. T. A. Brown, and H. Moseley, “Modelling fluorescence in clinical photodynamic therapy,” Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 12, 203–213 (2013).
[Crossref]

2012 (1)

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

2011 (1)

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

2009 (1)

D. Trivedi and E. M. Messing, “Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria,” BMC Urol. 9, 13 (2009).
[Crossref]

2006 (1)

A. Kumar, R. Kumar, and N. P. Gupta, “Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer,” Jpn. J. Clin. Oncol. 36, 172–175 (2006).
[Crossref]

Ali, S.

S. Ali, C. Daul, E. Galbrun, F. Guillemin, and W. Blondel, “Anisotropic motion estimation on edge preserving Riesz wavelets for robust video mosaicing,” Pattern Recognit. 51, 425–442 (2016).
[Crossref]

S. Ali, C. Daul, E. Galbrun, and W. Blondel, “Illumination invariant optical flow using neighborhood descriptors,” Comput. Vis. Image Underst. 145, 95–110 (2016).
[Crossref]

Amend, B.

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

Bedke, J.

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

Bellomo, F.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Billia, M.

G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Med. 11, 13 (2013).
[Crossref]

Blondel, W.

S. Ali, C. Daul, E. Galbrun, F. Guillemin, and W. Blondel, “Anisotropic motion estimation on edge preserving Riesz wavelets for robust video mosaicing,” Pattern Recognit. 51, 425–442 (2016).
[Crossref]

S. Ali, C. Daul, E. Galbrun, and W. Blondel, “Illumination invariant optical flow using neighborhood descriptors,” Comput. Vis. Image Underst. 145, 95–110 (2016).
[Crossref]

Bray, F.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
[Crossref]

Brown, C. T. A.

R. M. Valentine, S. H. Ibbotson, K. Wood, C. T. A. Brown, and H. Moseley, “Modelling fluorescence in clinical photodynamic therapy,” Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 12, 203–213 (2013).
[Crossref]

Celestino, F.

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

Chen, Q.

W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
[Crossref]

Cheung, G.

G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Med. 11, 13 (2013).
[Crossref]

Cheung, W. W. L.

M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
[Crossref]

Cindolo, L.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Cosciani Cunico, S.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Cui, Z.

W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
[Crossref]

Dasgupta, P.

G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Med. 11, 13 (2013).
[Crossref]

Daul, C.

S. Ali, C. Daul, E. Galbrun, F. Guillemin, and W. Blondel, “Anisotropic motion estimation on edge preserving Riesz wavelets for robust video mosaicing,” Pattern Recognit. 51, 425–442 (2016).
[Crossref]

S. Ali, C. Daul, E. Galbrun, and W. Blondel, “Illumination invariant optical flow using neighborhood descriptors,” Comput. Vis. Image Underst. 145, 95–110 (2016).
[Crossref]

De Carlo, F.

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

Di Stasi, S. M.

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

Esfahani, E. T.

K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
[Crossref]

Ferlay, J.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
[Crossref]

Fujita, H.

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Fukuhara, H.

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Fung, F. D. H.

M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
[Crossref]

Furihata, M.

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Galbrun, E.

S. Ali, C. Daul, E. Galbrun, F. Guillemin, and W. Blondel, “Anisotropic motion estimation on edge preserving Riesz wavelets for robust video mosaicing,” Pattern Recognit. 51, 425–442 (2016).
[Crossref]

S. Ali, C. Daul, E. Galbrun, and W. Blondel, “Illumination invariant optical flow using neighborhood descriptors,” Comput. Vis. Image Underst. 145, 95–110 (2016).
[Crossref]

Giannella, R.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Goggins, W. B.

M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
[Crossref]

Goodison, S.

S. Goodison, C. J. Rosser, and V. Urquidi, “Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests,” Mol. Diagn. Ther. 17, 71–84 (2013).
[Crossref]

Guillemin, F.

S. Ali, C. Daul, E. Galbrun, F. Guillemin, and W. Blondel, “Anisotropic motion estimation on edge preserving Riesz wavelets for robust video mosaicing,” Pattern Recognit. 51, 425–442 (2016).
[Crossref]

Gupta, N. P.

A. Kumar, R. Kumar, and N. P. Gupta, “Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer,” Jpn. J. Clin. Oncol. 36, 172–175 (2006).
[Crossref]

Guru, K. A.

K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
[Crossref]

Hennenlotter, J.

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

Hussein, A. A.

K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
[Crossref]

Ibbotson, S. H.

R. M. Valentine, S. H. Ibbotson, K. Wood, C. T. A. Brown, and H. Moseley, “Modelling fluorescence in clinical photodynamic therapy,” Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 12, 203–213 (2013).
[Crossref]

Inoue, K.

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Jemal, A.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
[Crossref]

Jin, X.

W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
[Crossref]

Kang, W.

W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
[Crossref]

Khan, A.

K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
[Crossref]

Khan, M. S.

G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Med. 11, 13 (2013).
[Crossref]

Kruck, S.

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

Kumar, A.

A. Kumar, R. Kumar, and N. P. Gupta, “Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer,” Jpn. J. Clin. Oncol. 36, 172–175 (2006).
[Crossref]

Kumar, R.

A. Kumar, R. Kumar, and N. P. Gupta, “Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer,” Jpn. J. Clin. Oncol. 36, 172–175 (2006).
[Crossref]

Kurabayashi, A.

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Lapini, A.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Leung, C.

M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
[Crossref]

Martini, T.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Masala, A.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Masedu, F.

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

Merseburger, A.

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

Messing, E. M.

D. Trivedi and E. M. Messing, “Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria,” BMC Urol. 9, 13 (2009).
[Crossref]

Minervini, A.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Moseley, H.

R. M. Valentine, S. H. Ibbotson, K. Wood, C. T. A. Brown, and H. Moseley, “Modelling fluorescence in clinical photodynamic therapy,” Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 12, 203–213 (2013).
[Crossref]

Ng, C. F.

M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
[Crossref]

Pagliarulo, V.

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

Pycha, A.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Riedl, C.

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

Rosser, C. J.

S. Goodison, C. J. Rosser, and V. Urquidi, “Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests,” Mol. Diagn. Ther. 17, 71–84 (2013).
[Crossref]

Sahai, A.

G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Med. 11, 13 (2013).
[Crossref]

Sasaki, J.

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Schips, L.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Shafiei, S. B.

K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
[Crossref]

Sharif, M.

K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
[Crossref]

Shuin, T.

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Siegel, R. L.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
[Crossref]

Sievert, K.-D.

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

Soerjomataram, I.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
[Crossref]

Stenzl, A.

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

Torre, L. A.

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
[Crossref]

Trivedi, D.

D. Trivedi and E. M. Messing, “Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria,” BMC Urol. 9, 13 (2009).
[Crossref]

Urquidi, V.

S. Goodison, C. J. Rosser, and V. Urquidi, “Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests,” Mol. Diagn. Ther. 17, 71–84 (2013).
[Crossref]

Utsumi, K.

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Valentine, R. M.

R. M. Valentine, S. H. Ibbotson, K. Wood, C. T. A. Brown, and H. Moseley, “Modelling fluorescence in clinical photodynamic therapy,” Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 12, 203–213 (2013).
[Crossref]

Verri, C.

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

Vittori, G.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Wong, M. C. S.

M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
[Crossref]

Wood, K.

R. M. Valentine, S. H. Ibbotson, K. Wood, C. T. A. Brown, and H. Moseley, “Modelling fluorescence in clinical photodynamic therapy,” Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 12, 203–213 (2013).
[Crossref]

Zani, D.

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Zhang, D.

W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
[Crossref]

Zhang, H.

W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
[Crossref]

BMC Med. (1)

G. Cheung, A. Sahai, M. Billia, P. Dasgupta, and M. S. Khan, “Recent advances in the diagnosis and treatment of bladder cancer,” BMC Med. 11, 13 (2013).
[Crossref]

BMC Urol. (1)

D. Trivedi and E. M. Messing, “Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria,” BMC Urol. 9, 13 (2009).
[Crossref]

CA Cancer J. Clin. (1)

F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin. 68, 394–424 (2018).
[Crossref]

Comput. Vis. Image Underst. (1)

S. Ali, C. Daul, E. Galbrun, and W. Blondel, “Illumination invariant optical flow using neighborhood descriptors,” Comput. Vis. Image Underst. 145, 95–110 (2016).
[Crossref]

Jpn. J. Clin. Oncol. (1)

A. Kumar, R. Kumar, and N. P. Gupta, “Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer,” Jpn. J. Clin. Oncol. 36, 172–175 (2006).
[Crossref]

Mol. Diagn. Ther. (1)

S. Goodison, C. J. Rosser, and V. Urquidi, “Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests,” Mol. Diagn. Ther. 17, 71–84 (2013).
[Crossref]

Oncotarget (1)

W. Kang, Z. Cui, Q. Chen, D. Zhang, H. Zhang, and X. Jin, “Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: a systematic review and meta-analysis,” Oncotarget 8, 23880–23890 (2016).
[Crossref]

Pattern Recognit. (1)

S. Ali, C. Daul, E. Galbrun, F. Guillemin, and W. Blondel, “Anisotropic motion estimation on edge preserving Riesz wavelets for robust video mosaicing,” Pattern Recognit. 51, 425–442 (2016).
[Crossref]

Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. (1)

R. M. Valentine, S. H. Ibbotson, K. Wood, C. T. A. Brown, and H. Moseley, “Modelling fluorescence in clinical photodynamic therapy,” Photochem. Photobiol. Sci. Off. J. Eur. Photochem. Assoc. Eur. Soc. Photobiol. 12, 203–213 (2013).
[Crossref]

Photodiagnosis Photodyn. Ther. (1)

H. Fukuhara, K. Inoue, A. Kurabayashi, M. Furihata, H. Fujita, K. Utsumi, J. Sasaki, and T. Shuin, “The inhibition of ferrochelatase enhances 5-aminolevulinic acid-based photodynamic action for prostate cancer,” Photodiagnosis Photodyn. Ther. 10, 399–409 (2013).
[Crossref]

Sci. Rep. (1)

M. C. S. Wong, F. D. H. Fung, C. Leung, W. W. L. Cheung, W. B. Goggins, and C. F. Ng, “The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection,” Sci. Rep. 8, 1129 (2018).
[Crossref]

Surg. Endosc. (1)

A. Lapini, A. Minervini, A. Masala, L. Schips, A. Pycha, L. Cindolo, R. Giannella, T. Martini, G. Vittori, D. Zani, F. Bellomo, and S. Cosciani Cunico, “A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study,” Surg. Endosc. 26, 3634–3641 (2012).
[Crossref]

Ther. Adv. Urol. (1)

S. M. Di Stasi, F. De Carlo, V. Pagliarulo, F. Masedu, C. Verri, F. Celestino, and C. Riedl, “Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder,” Ther. Adv. Urol. 7, 339–350 (2015).
[Crossref]

Urol. Int. (1)

S. Kruck, J. Bedke, J. Hennenlotter, B. Amend, A. Merseburger, A. Stenzl, and K.-D. Sievert, “Virtual bladder tumor transurethral resection: an objective evaluation tool to overcome learning curves with and without photodynamic diagnostics,” Urol. Int. 87, 138–142 (2011).
[Crossref]

Urology (1)

K. A. Guru, S. B. Shafiei, A. Khan, A. A. Hussein, M. Sharif, and E. T. Esfahani, “Understanding cognitive performance during robot-assisted surgery,” Urology 86, 751–757 (2015).
[Crossref]

Other (1)

Great Britain, Parliament, House of Commons, Science and Technology Committee, Bridging the Valley of Death: Improving the Commercialisation of Research, Eighth Report of Session 2012-13, Report, Together with Formal Minutes, Oral and Written Evidence (The Stationery Office, 2013).

Cited By

OSA participates in Crossref's Cited-By Linking service. Citing articles from OSA journals and other participating publishers are listed here.

Alert me when this article is cited.


Figures (4)

Fig. 1.
Fig. 1. (a) CyPaM2 device made for fluorescence assisted–transurethral resection of bladder cancer (FA-TURB). It consists of a camera head (i) connected to a telescope (ii) for photodynamic diagnosis (Karl Storz Endoskope), a light source box (iii) including a white LED and a 405 nm laser diode (for PpIX excitation), a camera box (iv) allowing digital recording of video streams. (b) Light sources, camera recording, and mosaicking software are driven by a dedicated interface hosted on a medical panel PC shown in the right picture (v) (WPM-249, Wincomm) used for the bimodal display of the video streams and for the panoramic image building and display.
Fig. 2.
Fig. 2. Screenshot of the bimodal video stream display on the CyPaM2 device. The bulb and the LASER icons on the right side of the screen are used for the remote light control. In the bottom right corner, the camera icon allowed the taking of pictures, the video camera icon allowed video stream digital recording, and the “M10” video icon allowed the automatic launching of a 10 s video stream recording and the corresponding mosaic building.
Fig. 3.
Fig. 3. Output mosaic built from a 10 s video sequence using the CyPaM2 device.
Fig. 4.
Fig. 4. Images extracted from (a) the white-light video sequence and (b) the fluorescence video sequence that correspond to the white circle shown in (c) the panoramic image that was built out of circa 150 frames taken from the fluorescence video sequence. Blue background is due to the blue-light excitation; red surfaces of the bladder lining correspond to protoporphyrin IX fluorescence emission and therefore to potentially cancerous lesions.

Tables (3)

Tables Icon

Table 1. Optical Image Quality of the CyPaM2 and the Reference Devices Evaluated by the Urologist on a Quantitative Scale Ranging from 0 (Low Quality) to 10 (High Quality) a

Tables Icon

Table 2. Reference Device Use of Ergonomics Evaluated by the Urologist for the Nine Patients According to the NASA-TLX Scale

Tables Icon

Table 3. CyPaM2 Device Use of Ergonomics Evaluated by the Urologist for the Nine Patients According to the NASA-TLX Scale

Metrics